Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cidan is a Traditional Chinese Medicine (TCM) botanical formula used as an adjuvant therapy for hepatocellular carcinoma (HCC). It consists of over ten plant extracts and is typically administered in capsule form. In clinical practice, it is often combined with Transcatheter Arterial Chemoembolization (TACE) to improve efficacy and reduce treatment-related toxicity. The formula is intended to prevent recurrence in high-risk postoperative HCC patients by leveraging the synergistic effects of its various botanical components, which are thought to provide antitumor and immunomodulatory benefits. It has been utilized in clinical settings for over a decade as a safe and non-toxic therapeutic option.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cidan.